TP53 and acute myeloid leukemia: Patients showing TP53-mut (n = 9) were also associated with shorter OS (p = 0.015, Fig. 5B), while DNMT3A-mut was not significant (p = 0.242), although there was also a low number of patients who presented with DNMT3A-mut (n = 5) in this subset of younger AML patients (<60 years of age).